Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics Inc. (LUCD)
NASDAQ:LUCD
LUCD Stock Chart & Stats
$1.22
>-$0.01(-1.09%)
At close: 4:00 PM EST
$1.22
>-$0.01(-1.09%)
Day’s Range― - ―
52-Week Range$0.95 - $1.80
Previous CloseN/A
Volume130.18K
Average Volume (3M)1.93M
Market Cap
$190.09M
Enterprise Value$124.56M
Total Cash (Recent Filing)$47.33M
Total Debt (Recent Filing)$24.34M
Price to Earnings (P/E)―
Beta0.05
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding131,098,750
10 Day Avg. Volume658,155
30 Day Avg. Volume1,931,035
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)7.67
Price to Sales (P/S)9.52
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue28.32
Enterprise Value/Gross Profit-41.53
Enterprise Value/Ebitda-2.32
Forecast
1Y Price Target
$8.25Price Target Upside576.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Medicare Coverage ProgressA unanimous Medicare advisory endorsement materially raises the probability of durable coverage and standardized reimbursement. Structural Medicare coverage would expand access to older patients, reduce payer fragmentation, improve collections, and support sustained test volume growth over multiple years.
VA National Contract AwardedA nationwide VA Federal Supply Schedule contract creates a stable, large integrated-channel for tests and secures price parity with Medicare. This durable procurement pathway can drive predictable volumes, simplify contracting, and reduce commercial sales dependency over the medium term.
Strengthened Cash Runway After FinancingThe recent capital raise meaningfully extends runway, giving management time to execute reimbursement wins and scale testing operations. Adequate near-term liquidity supports investments in market access and operations that are necessary to convert regulatory progress into sustainable revenue.
Bears Say
Chronic Unprofitable OperationsPersistent negative margins and cash burn indicate the business has yet to convert growth into profitability. This structural loss-making profile requires ongoing financing, limits reinvestment capacity, and increases execution risk if reimbursement gains fail to translate into sustainable unit economics.
High Leverage And Weak ReturnsSignificant leverage and negative ROE raise insolvency and refinancing risk, especially if revenue growth slows. Interest and principal obligations will constrain free cash flow and strategic flexibility, making long-term investment in commercialization and payer negotiations more challenging.
Ongoing Reimbursement DenialsFrequent denials and authorization hurdles are a structural barrier to revenue realization and clinician adoption. They increase administrative costs, lengthen cash collection cycles, and make realized revenue per test unpredictable, undermining the firm's ability to scale profitably over time.
Lucid Diagnostics News
LUCD FAQ
What was Lucid Diagnostics Inc.’s price range in the past 12 months?
Lucid Diagnostics Inc. lowest stock price was $0.95 and its highest was $1.80 in the past 12 months.
What is Lucid Diagnostics Inc.’s market cap?
Lucid Diagnostics Inc.’s market cap is $190.09M.
When is Lucid Diagnostics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Lucid Diagnostics Inc.’s earnings last quarter?
Currently, no data Available
Is Lucid Diagnostics Inc. overvalued?
According to Wall Street analysts Lucid Diagnostics Inc.’s price is currently Undervalued.
Does Lucid Diagnostics Inc. pay dividends?
Lucid Diagnostics Inc. does not currently pay dividends.
What is Lucid Diagnostics Inc.’s EPS estimate?
Lucid Diagnostics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lucid Diagnostics Inc. have?
Lucid Diagnostics Inc. has 131,098,750 shares outstanding.
What happened to Lucid Diagnostics Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lucid Diagnostics Inc.?
Currently, no hedge funds are holding shares in LUCD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lucid Diagnostics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.25 (576.23% Upside)
$8.25 (576.23% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 29.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.03%
12-Months-Change
Fundamentals
Return on Equity
-331.24%
Trailing 12-Months
Asset Growth
135.41%
Trailing 12-Months
Company Description
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
LUCD Company Deck
LUCD Earnings Call
Q3 2025
0:00 / 0:00
LUCD Stock 12 Month Forecast
Average Price Target
$8.25
▲(576.23% Upside)
Technical Analysis
Ownership Overview
2.52% Insiders
4.47% Mutual Funds
3.54% Other Institutional Investors
83.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---